The FDA on June 6, 2017 approved GLEOLAN® as an optical imaging agent, indicated in patients with Gliomas (suspected World Health Organization Grades III or IV on preoperative imaging), as an adjunct for the visualization of malignant tissue during surgery. GLEOLAN® is a product of NX Development Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
